Cargando…
For love and money: the need to rethink benefits in HIV cure studies
HIV cure research holds great potential to eradicate HIV, but the benefit to early trial participants is likely to be small. Moreover, participation carries unknown and possibly significant risks to research participants. This is the risk:benefit ratio challenge of HIV cure research. Although it may...
Autor principal: | Largent, Emily |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293850/ https://www.ncbi.nlm.nih.gov/pubmed/27193021 http://dx.doi.org/10.1136/medethics-2015-103119 |
Ejemplares similares
-
An activist's argument that participant values should guide risk–benefit ratio calculations in HIV cure research
por: Evans, David
Publicado: (2017) -
Contractualist reasoning, HIV cure clinical trials, and the moral (ir)relevance of the risk/benefit ratio
por: Kumar, Rahul
Publicado: (2017) -
The social value of candidate HIV cures: actualism versus possibilism
por: Brown, Regina, et al.
Publicado: (2017) -
Must research benefit human subjects if it is to be permissible?
por: Wikler, Daniel
Publicado: (2017) -
Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
por: Conaghan, Philip G., et al.
Publicado: (2021)